Please login to the form below

Not currently logged in

AZ's Q3 income up as sales stay flat

AstraZeneca's total net income jumped from $1.83bn to $3.13bn in the pharmaceutical company's financial results for the third quarter of 2011, despite sales falling by 2 per cent

AstraZeneca's (AZ) total net income jumped from $1.83bn to $3.13bn in the pharmaceutical company's financial results for the third quarter of 2011.

The increase was largely due to a growth in reporting operating profit of 78 per cent, including $1.48bn from the sale of its Sweden-based dental and devices business Astra Tech to Dentsply.

AZ's total revenue for the period was $8.21bn, a decrease of 2 per cent at constant exchange rates from 2010.

The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort (budesonide/formoterol) for respiratory disorders.

Products affected by generic competition included heartburn treatment Nexium (esomeprazole), with sales falling by 16 per cent in the US and 50 per cent in Western Europe.

Breast cancer therapy Arimidex (anastrozole) was also hit hard, with US sales falling by 81 per cent and Western European sales down by 65 per cent.

Regionally, Western Europe was the worst affected area overall, with revenue down by 15 per cent. US revenue remained level, while, in emerging markets, it grew 7 per cent.

David Brennan, CEO, said: "We have delivered a third quarter revenue and core earnings performance in line with our expectations, against the backdrop of anticipated generic competition and government price interventions."

27th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...